1 results
Approved WMORecruitment stopped
To assess the prevalence of LDL-C >1.8 mMol/L in a subgroup of very high risk patients with ASCVD, who remain at a very high-residual risk for ACS, despite treatment with high-intensity statins in combination with ezetimibe. This subgroup of…